Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing

For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with blinatumomab, a CD19/CD3 bispecific antibody construct (BiTE(®)), or with chimeric antigen receptor T cells (CAR-T) has shown great promise for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Sandra L., Sherman, Marika, McElroy, Patricia L., Lofgren, Julie A., Moody, Gordon, Baeuerle, Patrick A., Coxon, Angela, Arvedson, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570333/
https://www.ncbi.nlm.nih.gov/pubmed/28837681
http://dx.doi.org/10.1371/journal.pone.0183390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570333/
https://www.ncbi.nlm.nih.gov/pubmed/28837681
http://dx.doi.org/10.1371/journal.pone.0183390

Ejemplares similares